Overview

Efficacy and Safety Study of ABT-288 in Subjects With Mild-to-Moderate Alzheimer's Disease

Status:
Completed
Trial end date:
2011-02-01
Target enrollment:
Participant gender:
Summary
Efficacy and safety study of ABT-288 in adults with mild-to-moderate Alzheimer's disease.
Phase:
Phase 2
Details
Lead Sponsor:
AbbVie (prior sponsor, Abbott)
Treatments:
Donepezil